Izraēla - ivrits - Ministry of Health

devries & co. ltd - gemcitabine 200 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap

Izraēla - ivrits - Ministry of Health

devries & co. ltd - gemcitabine 1000 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap

Izraēla - ivrits - Ministry of Health

pfizer pharmaceuticals israel ltd - doxorubicin hydrochloride 10 mg / 5 ml - solution for injection - doxorubicin - adriblastina has been used successfully to produce regression in a variety of neoplastic conditions, such as carcinoma of the breast, lung, bladder, thyroid, and also ovarian carcinomas, bone and soft-tissue sarcomas, hodgkin's lymphomas, neuroblastomas, wilms tumour, acute lymphoblastic leukaemia and acute myeloblastic leukaemia

Izraēla - ivrits - Ministry of Health

pfizer pharmaceuticals israel ltd - doxorubicin hydrochloride 50 mg / 25 ml - solution for injection - doxorubicin - adriblastina has been used successfully to produce regression in a variety of neoplastic conditions, such as carcinoma of the breast, lung, bladder, thyroid, and also ovarian carcinomas, bone and soft-tissue sarcomas, hodgkin's and non- hodgkin's lymphomas, neuroblastomas, wilms tumour, acute lymphoblastic leukaemia and acute myeloblastic leukaemia

Izraēla - ivrits - Ministry of Health

salomon,levin & elstein ltd - epirubicin hydrochloride 2 mg / 1 ml - solution for injection / infusion - epirubicin - for the treatment of wide spectrum of neoplastic diseases, including:- breast carcinoma- lung carcinoma - high doses- ovarian carcinoma- gastric carcinomas- soft tissue sarcoma- i.v. administration for the treatment of advanced bladder carcinoma- intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection.

Izraēla - ivrits - Ministry of Health

inovamed ltd - epirubicin hydrochloride - תמיסה להזרקה - epirubicin hydrochloride 2 mg / 1 ml - epirubicin - epirubicin - for the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma high doses, ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. i.v. administration for the treatment of advanced bladder carcinoma.

Izraēla - ivrits - Ministry of Health

abic marketing ltd, israel - cisplatin - תרכיז להכנת תמיסה לאינפוזיה - cisplatin 1 mg/ml - cisplatin - cisplatin - palliative therapy to be employed either alone, or more commonly in established combination therapy with orher approved chemotherapeutic agents and in patients with metastatic testicular tumor and metastatic ovarian tumor who have alreasy received appropriate surgical and/or radiotherapeutic procedures and in patients with advanced bladder cancer.

Izraēla - ivrits - Ministry of Health

abic marketing ltd, israel - carboplatin - תרכיז להכנת תמיסה לאינפוזיה - carboplatin 10 mg/ml - carboplatin - carboplatin - advanced ovarian carcinoma in initial treatment and secondary treatment. metastatic small cell carcinoma of the lung.

Izraēla - ivrits - Ministry of Health

pharmalogic ltd - carboplatin 10 mg/ml - solution for infusion - carboplatin - carboplatin is used alone or in combination with other antineoplastic agents in the treatment of advanced ovarian carcinoma and metastatic small cell lung cancer.

Izraēla - ivrits - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig